Relapsed/Refractory Malignant Lymphomas Clinical Trial
Official title:
A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation
Nowadays there is no randomized trials for comparison the effectiveness and tolerability of
different conditioning regimens.
Bendamustine is a unique chemotherapeutic agent that combines alkylating action of nitrogen
mustard and the activity of purine antimetabolite. Bendamustine has shown its effectiveness
for the treatment of patients with chronic lymphoproliferative diseases such as chronic
lymphocytic leukemia and several indolent lymphomas. The literature also presents evidence of
the effectiveness bendamustine in patients with Hodgkin's lymphoma who received multiple
lines of prior chemotherapy, including high dose chemotherapy and transplantation of
peripheral hematopoietic stem cells. There are also data of using bendamustine as a part of
conditioning regimen.
In this context, it was planned a study for evaluation the safety and effectiveness of the
BeEAC (bendamustine, etoposide, cytarabine, cyclophosphamide) conditioning regimen prior to
autologous transplantation of peripheral hematopoietic stem cells for the treatment of
relapsed/refractory malignant lymphomas.
n/a